CXCL16 and CXCR6 in Ewing sarcoma family tumor

• Published in: Human pathology 2014-04, Vol.45 (4), p.753-760
• Main Authors: Na, Ki Yong, Kim, Hyun-Sook, Jung, Woon-Won, Sung, Ji-Youn, Kalil, Ricardo Karam, Kim, Youn Wha, Park, Yong-Koo, MD
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Angiogenesis; Biomarkers, Tumor - analysis; Bone cancer; Bone Neoplasms - metabolism; Bone Neoplasms - mortality; Bone Neoplasms - pathology; Cell culture; Cell Line, Tumor; Chemokine CXCL16; Chemokines; Chemokines, CXC - analysis; Chemokines, CXC - biosynthesis; Child; Child, Preschool; CXCL16; CXCR6; Disease Susceptibility; Ewing sarcoma; Ewing sarcoma family tumor; Female; Gene expression; Humans; Immunohistochemistry; Infant; Kaplan-Meier Estimate; Kinases; Male; Middle Aged; Multivariate analysis; Pathology; Polymerase chain reaction; Prognosis; Proportional Hazards Models; Radiation therapy; Real-Time Polymerase Chain Reaction; Receptors, Chemokine - analysis; Receptors, Chemokine - biosynthesis; Receptors, CXCR6; Receptors, Scavenger - analysis; Receptors, Scavenger - biosynthesis; Receptors, Virus - analysis; Receptors, Virus - biosynthesis; RNA, Messenger - analysis; Sarcoma, Ewing - metabolism; Sarcoma, Ewing - mortality; Sarcoma, Ewing - pathology; Studies; Transcriptome; Tumors; Young Adult
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2013.09.017

Summary Chemokines are a family of peptide mediators that play an essential role in cellular migration and intracellular communication in tumor cells as well as immune cells. We hypothesized that the CXCL16-CXCR6 ligand-receptor system plays an important role in Ewing sarcoma (ES) family tumor (ESFT) progression. Using real-time quantitative reverse transcription–polymerase chain reaction, we investigated the mRNA expression of CXCL16, CXCR6, and ADAM 10 in various cell lines. We also investigated the expression of CXCL16, CXCR6, ADAM 10, and ADAM 17 in tissue samples from 61 ESFT patients using immunohistochemistry. The mRNA expression levels of CXCL16 and CXCR6 in the ES cell line were higher than those in the other cell lines. Immunohistochemical staining revealed that CXCL16 and CXCR6 were highly expressed in tumor cells of ESFT and showed a positive correlation between them. The expression of CXCL16 and CXCR6 was associated with the occurrence of lung metastasis. Univariate analysis revealed that CXCL16 or CXCR6 expression was associated with worse prognosis of ESFT patients. In addition, CXCL16 and CXCR6 expression was associated with shorter overall survival irrespective of other prognostic factors. Our results suggest that the CXCL16/CXCR6 axis appears to be important in the progression of ESFT, resulting in more aggressive clinical behavior. Furthermore, there may be a decrease in the overall survival in ESFT patients who have tumors that stain strongly for CXCL16 and CXCR6.